Trials / Completed
CompletedNCT00586105
Phase III Study of Sorafenib in Patients With Renal Cell Carcinoma (RCC)
A Multicenter Uncontrolled Study of Sorafenib in Patients With Unresectable and/or Metastatic Renal Cell Carcinoma
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 39 (actual)
- Sponsor
- Bayer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
A multicenter uncontrolled study of sorafenib in patients with unresectable and/or metastatic renal cell carcinoma (RCC) to assess the pharmacokinetic profile, safety and tolerability, and efficacy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Sorafenib (Nexavar, BAY43-9006) | 400 mg (2 tablets of 200 mg) of sorafenib per oral (PO) twice daily (BID) |
Timeline
- Start date
- 2005-12-01
- Primary completion
- 2008-05-01
- Completion
- 2008-05-01
- First posted
- 2008-01-04
- Last updated
- 2014-04-16
- Results posted
- 2010-10-01
Locations
8 sites across 2 countries: China, Taiwan
Source: ClinicalTrials.gov record NCT00586105. Inclusion in this directory is not an endorsement.